Overview

Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.
Phase:
Phase 2
Details
Lead Sponsor:
Ferring Pharmaceuticals
Treatments:
Quinagolide